|
 |
VidazaThis page contains recent news articles, when available, and an overview of Vidaza but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Researchers from France have reported a response rate of 21% and a one-year survival following treatment with Vidaza® (5-azacitidine) for patients with ... Cancer Consultants Health Canada Approves Celgene's Vidaza For Blood Disorder Treatment - Update - Dec 10, 2009 ...(CELG: News ) said its Vidaza has received approval from Canadian regulatory body Health Canada for treatment of Intermediate-2 and High-risk ... RTT News Local man tests drug designed to fend off cancer - Dec 28, 2009 Patient Ted Arbour, right, prepares to receive the drug Vidaza, from Windsor Regional Cancer Centre nurse ... Windsor Star Approved Vidaza Dosing Schedule May Be Better And Safer Than Alternatives (ASH ... - Dec 14, 2009 The dosing schedule of Vidaza (azacitidine) currently approved for use in Europe may be the most effective and safest treatment plan for myelodysplastic ... The MDS Beacon Celgene remains in an uptrend - Dec 21, 2009 ...for Celgene's FY2010 revenue to increase 20-23%, on top of a likely a 15-20% rise in FY2009, boosted by cancer treatments Revlimid's and Vidaza's sales. ... BloggingStocks (blog) Beacon NewsFlashes – December 13, 2009 - Dec 13, 2009 Canada Approves Vidaza For High-Risk MDS Patients — Health Canada, the nation's drug regulator, has approved the sale and use of Vidaza (azacitidine) in ... The MDS Beacon MDS Patients Are Responsive To Sapacitabine, According To Interim Phase 2 ... - Dec 18, 2009 Dacogen (decitabine) or Vidaza (azacitidine). The participants have been divided into three groups receiving three different doses of sapacitabine. ... The MDS Beacon Epigenetics research takes aim at cancer, Alzheimer's, autism, other illnesses - Dec 14, 2009 Azacitidine, sold as Vidaza and used to treat bone-marrow cancer and blood disorders, became the first FDA-approved epigenetic drug in 2004. ... Washington Post EpiCept Provides Clinical and Business Update on Ceplene Program - Dec 15, 2009 The initiation of a study led by GFM (Groupe Francophone des Myélodysplasies) that will examine the effects of Ceplene/IL-2 in combination with Vidaza ... PharmaLive.com (press release) Celgene Corporation (NASDAQ:CELG) to Present at Deutsche - Dec 10, 2009 The Company's commercial stage products include REVLIMID, THALOMID (inclusive of Thalidomide Pharmion), VIDAZA, ALKERAN and FOCALIN. On March 7, 2008, ... TransWorldNews (press release) Deals of the Week: Holiday Shopping - Dec 11, 2009 ...it would not need to add to its marketing and sales infrastructure since it already sells hematological cancer drugs Revlimid, Thalomid and Vidaza. ... The IN VIVO Blog (blog) Celgene Scores with Multiple Myeloma Treatment Revlimid - Dec 21, 2009 In addition to Revlimid, the company's product portfolio includes Vidaza for MDS, which should also drive growth. However, sales of Celgene's Thalomid have ... Seeking Alpha (blog) L'approbation par Santé Canada de VIDAZA(R) marque une nouvelle ère de ... - Dec 10, 2009 .../CNW/ - Santé Canada a approuvé VIDAZA (azacitidine), une importante option de traitement pour les formes avancées d'un groupe de troubles sanguins graves. ... CNW Telbec (Communiqué de presse) الإيبيجنتكس يتلاعب بØمضنا النوويّ - Dec 20, 2009 Ù?أصبØت مادة أزادسيتيدين الكيماوية التي تÙ?باع تØت اسم Vidaza وتÙ?ستخدم لعلاج سرطان النقي (نسيج داخل العظام) واضطرابات الدم، أول عقار Ù…Ù?صادق عليه من إدارة ... الجريدة Celgene покупает Gloucester Pharmaceuticals Inc., что дает ей возможноÑ?Ñ‚ÑŒ ... - Dec 10, 2009 Портфель Celgene включает Revlimid, применÑ?емый против множеÑ?твенной миеломы, неходжкинÑ?кой лимфомы, хроничеÑ?кого лимфолейкоза и Vidaza, предназначенный длÑ? ... Журнал Ремедиум Celgene Corporation Q3 2009 Earnings Call Transcript - Oct 22, 2009 And we are successfully commercializing REVLIMID and VIDAZA worldwide with continuous gains in market share. Focusing on REVLIMID, its long-term trajectory ... Seeking Alpha (blog) SuperGen-Glaxo Deal Couldn't Have Come at a Better Time - Oct 27, 2009 With sales of its lead drug losing headway to rival Celgene's (CELG) Vidaza, striking a deal with GlaxoSmithKline (GSK) to collaborate on cancer drug ... Seeking Alpha (blog) Celgene Reports Record Third Quarter 2009 Operating and Financial Results - Oct 22, 2009 VIDAZA net sales were $103.1 million, an increase of 62 percent over sales in the third quarter of 2008. Revenue from Focalin® and the Ritalin® family of ... Reuters Celgene (CELG): Bet on biotech for 'offense and defense' - Oct 27, 2009 They have a number of products at the commercial stage including REVLIMID, THALOMID and VIDAZA. "Celgene is also researching stem cells derived from the ... BloggingStocks (blog) Valproic Acid May Enhance Efficacy Of Vidaza For Myelodysplastic Syndromes - Oct 21, 2009 A combination therapy of Vidaza (azacitidine) and valproic acid (Depakene) may be more effective than Vidaza alone for the treatment of myelodysplastic ... The MDS Beacon Celgene Corp. Reports Operating Results (10-Q) - Oct 30, 2009 VIDAZA® net sales increased by $39.6 million to $103.1 million for the three-month period ended September 30, 2009 compared to the three-month period ended ... GuruFocus.com InterMune Announces Appointments of Senior Leadership to Prepare for Potential ... - Nov 5, 2009 Most recently at Pharmion (acquired by Celgene), Ms. Shoemaker was responsible for creating the commercial organization and the successful launch of Vidaza® ... Reuters More Than 200 Abstracts Evaluating Celgene Products across a Range of ... - Nov 11, 2009 VIDAZA ® , THALOMID ® , pomalidomide, ACE-011 and Amrubicin at the 51st Annual American Society of Hematology Meeting and Exposition from December 5-8, ... WELT ONLINE The H1N1 Swine Flu Vaccine And Myelodysplastic Syndromes: A Comprehensive Review - Nov 5, 2009 However, it has been suggested by some doctors that patients wait until the end of treatment cycles of drugs such as Vidaza before receiving the H1N1 ... The MDS Beacon Celgene Corporation - Pharmaceuticals & Healthcare - Deals and Alliances ... - Nov 9, 2009 The company has three marketed products REVLIMID, THALOMID and VIDAZA. It is headquartered in Summit, New Jersey, United States Pharmaceuticals & Healthcare ... PR-Inside.com (Pressemitteilung) Updated NCCN Guidelines for AML Include Risk Stratification to Assist in ... - Oct 19, 2009 In the updated NCCN Guidelines, 5-azacytidine (Vidaza(R), Celgene Corporation) and decitabine (Dacogen(R), Eisai Inc.), have been added as low intensity ... Reuters Celgene Reports Record Third Quarter 2009 Operating and Financial Results - Oct 22, 2009 VIDAZA net sales were $103.1 million, an increase of 62 percent over sales in the third quarter of 2008. Revenue from Focalin ® and the Ritalin ® family of ... Business Wire (press release) NCCN updates clinical practice guidelines for AML, NHL - Oct 30, 2009 Under category 2B designations, the guidelines panel also added 5-azacytidine (Vidaza, Celgene Corporation) and decitabine (Dacogen, Eisai Inc.) as ... HemOncToday Commercial Insight: Cytotoxic Therapies - Market growth will slow due to ... - Oct 30, 2009 The launch of Dacogen (decitabine; Eisai/Johnson & Johnson) and Vidaza (azacitidine; Celgene) in the 5EU and Japanese markets will contribute significantly ... PRMinds (press release) www.StockMarketingInc.com: Wake Up People!! Sign Up For The Free Newsletter ... - Nov 5, 2009 Ms. Shoemaker was responsible for creating the commercial organization and the successful launch of Vidaza(R), a chemotherapeutic agent for treating ... Trading Markets (press release) About this author: - Oct 21, 2009 Celgene (CELG) is expected to report Q3 earnings Thursday, October 22 before market open, with a conference call scheduled for 9:00 am ET. ... Seeking Alpha (blog) Celgene 盈馀高於预期，股价上扬4.6% - Oct 22, 2009 ...å…¬å?¸å…¬å¸ƒç¬¬ä¸‰å£Revlimid销售é¢?为4.29忆美元，市场预期4.29忆；Vidaza销售é¢?1.03忆美元，市场预期1.08忆美元；Thalomid销售é¢?1.1忆美元，市场预期1.02忆美元。 ... 凤凰网 Celgene erste Position eröffnen - Heibel-Ticker - Nov 2, 2009 Das noch junge Leukämie-Medikament Vidaza habe 103 Mio. USD zum Umsatz beigetragen, ein Anstieg um 62%. Weitere 110 Mio. USD Umsatz habe das Medikament ... Stock World Europe gives positive nod to Celgene's Vidaza - Oct 24, 2008 BOSTON, Oct 24 (Reuters) - Advisers to the European Commission recommended approval of the Celgene Corp (CELG.O) drug Vidaza as a treatment for a group of ... Reuters Celgene: Vidaza shows 'significant overall survival' benefit in EU... - Jun 13, 2008 SAN FRANCISCO (Thomson Financial) - Celgene Corp.'s Celgene International Sarl unit said Friday that data showed its Vidaza drug provides a 'significant ... Forbes Pharmion blood disorder drug Vidaza extends life - Aug 2, 2007 BOSTON, Aug 2 (Reuters) - Pharmion Corp. PHRM.O said on Thursday a late-stage trial of its drug Vidaza significantly extended the life of patients with ... Reuters Pharmion says FDA OKs intravenous use of Vidaza - Jan 29, 2007 Jan 29 (Reuters) - Pharmion Corp. PHRM.O said it won US regulatory approval for an intravenous version of its drug to treat patients with myelodysplastic ... Reuters Clinical Data on Vidaza(R) (Azacitidine for Injectable Suspension) in... - Dec 11, 2005 BOULDER, Colo., Dec. 11 /PRNewswire-FirstCall/ -- Pharmion Corporation reported today on several analyses of data from the Vidaza pivotal Phase III study. ... Free with registration - PR Newswire - AccessMyLibrary.com New Analysis Shows that VIDAZA Prolongs Survival in Patients - Dec 9, 2008 New Analysis Shows that VIDAZA Prolongs Survival in Patients with Higher-Risk Myelodysplastic Syndromes Results Presented at the 50^th Annual Meeting of the ... Bloomberg Vidaza study a factor in Pharmion sale - Dec 11, 2007 Patients who took Vidaza in a study lived a median 24.4 months, compared with 15 months for people on chemotherapy or best supportive care for a high-risk ... Rocky Mountain News Celgene/Pharmion Deal Paces Biotechs - Nov 19, 2007 Vidaza is designed to treat bone marrow diseases. Revlimid, Celgene's second biggest-selling drug, is basically an improved version of Thalomid. ... Forbes Celgene wins US approval to expand Vidaza label - Aug 21, 2008 BOSTON, Aug 21 (Reuters) - Celgene Corp (CELG.O) said on Thursday that US regulators have given it the green light to add information to the label of its ... Reuters Clinical Data on Vidaza(R) (Azacitidine for Injectable Suspension) in... - Jun 4, 2006 BOULDER, Colo., June 4 /PRNewswire-FirstCall/ -- Pharmion Corporation reported today findings from seven studies investigating the use of Vidaza(R) ... Free with registration - PR Newswire - AccessMyLibrary.com RPT-Pharmion Vidaza drug survival benefit confirmed - Dec 9, 2007 BOSTON, Dec 9 (Reuters) - Pharmion Corp PHRM.O said on Sunday that detailed analysis of a late-stage clinical trial of its drug to treat a group of blood ... Reuters New Data Demonstrate Clinical Activity of Vidaza(R) in Combination... - Dec 11, 2006 ORLANDO, Fla., Dec. 11 /PRNewswire-FirstCall/ -- Pharmion Corporation announced new data presented today from three studies of Vidaza(R) (azacitidine for ... RedOrbit NEW DATA VALIDATE VIDAZA RESPONSE RATES IN MDS. - Dec 12, 2006 Pharmion Corporation (Nasdaq: PHRM) announced new data presented today at the 48th Annual Meeting and Exposition of the American Society of Hematology (ASH) ... Free with registration - AsiaPulse News - AccessMyLibrary.com Pharmion investor says offer is too low - Feb 6, 2008 MGI Pharma Inc. (nasdaq: MOGN - news - people ) sells Dacogen, which is similar to Pharmion's blood-cancer treatment Vidaza. Both drugs are used for the ... Forbes … Corporation Announces FDA Acceptance Of Vidaza NDA Supplement For … - Jun 14, 2006 Pharmion Corporation (Nasdaq: PHRM) today announced that the US Food and Drug Administration (FDA) accepted for filing and established a six month review ... Medical News Today - Medical News Today (press release) Azacitidine (Vidaza) Is First Drug to Show Survival Benefit in... - Dec 12, 2005 By Bruce Sylvester. ATLANTA, GA -- December 12, 2005 -- A significantly higher percentage of elderly patients with high-risk myelodysplastic syndromes (MDS) ... DG News SuperGen drug fails trial; likely delay to European nod - Jul 1, 2008 O: Quote, Profile, Research) Vidaza, received approval from the US Food and ... "The Dacogen failure is a material positive for Celgene, as Vidaza is now ... Reuters India Clinical Data on Vidaza(R) (Azacitidine for Injectable Suspension) in... - Dec 8, 2005 BOULDER, Colo., Dec. 8 /PRNewswire-FirstCall/ -- Pharmion Corporation reported today that data from several Vidaza(R) studies will be presented at the ... Free with registration - PR Newswire - AccessMyLibrary.com FDA fast-tracks Pharmion's blood disorder drug - Aug 30, 2007 The drug, known by its trade name Vidaza, was developed by Pharmacia -- now Pfizer -- as a chemotherapy drug, but that use failed to win approval and the ... Bizjournals.com Celgene Beats Targets, Guides In Line - Jul 24, 2008 Sales of Thalomid came in at $131.6 million, edging past a $127 million expectation, and sales of myelodysplastic syndromes (MDS) drug Vidaza totaled $59.7 ... TheStreet.com - TheStreet.com (subscription) New Data Validate Vidaza(R) Response Rates In MDS And Report … - Dec 26, 2006 Pharmion Corporation (Nasdaq: PHRM) announced new data presented today at the 48th Annual Meeting and Exposition of the American Society of Hematology (ASH) ... Medical News Today - Medical News Today (press release) … Corporation Announces FDA Approval of Vidaza NDA Supplement for IV... - Jan 29, 2007 BOULDER, Colo., Jan. 29 /PRNewswire-FirstCall/ -- Pharmion Corporation announced today that it has received approval from the US Food and Drug ... Free with registration - PR Newswire - AccessMyLibrary.com Press Release: Clinical Data on Vidaza(R) (Azacitidine for Injectable... - Dec 11, 2005 Clinical Data on Vidaza(R) (Azacitidine for Injectable Suspension) in Higher-Risk MDS and AML Patients Presented at 47th Annual Meeting of American Society ... Pay-Per-View - PR Newswire - HighBeam Research Celgene Profit Swells on Cancer Drug Sales - Oct 23, 2008 Vidaza sales rose 50% to $64 million in the quarter. Vidaza sales are accelerating after Celgene relaunched the drug following the completion of the ... TheStreet.com - TheStreet.com (subscription) Drug stocks climb; Pharmion soars on drug data - Aug 2, 2007 The company said that Phase III clinical data for its drug Vidaza showed it could significantly extend the lives of patients with higher-risk ... MarketWatch … (PHRM) Submits New Drug Application (NDA) to FDA for Vidaza - Mar 30, 2006 Pharmion Corporation (Nasdaq: PHRM) announced the submission of a new drug application (NDA) supplement to add IV administration to instructions in the ... StreetInsider.com - StreetInsider.com (subscription) PHARMION BEATS STREET FORECAST - BOULDER-BASED DRUG … - Feb 15, 2005 After the firm announced regulatory approval for Vidaza, the company's stock price ... Vidaza sales will reach between $130 million and $140 million, ... $2.95 - Rocky Mountain News - NewsBank VIDAZA(R) Receives Expanded FDA Approval to Include Overall Survival ... - Aug 21, 2008 Celgene Corporation (Nasdaq:CELG) today announced VIDAZA (azacitidine) received expanded US Food and Drug Administration (FDA) approval to reflect new ... Genetic Engineering News - Genetic Engineering News (press release) Pharmion raises 2006 net sales outlook, sets 2007 view - Jan 9, 2007 Vidaza, which is already sold in the United States, treats a group of blood disorders called myelodysplastic syndromes that can lead to leukemia. ... Reuters Pharmion Corp announces enrollment of first patient into Vidaza patien... - Nov 1, 2006 Pharmion Corp announced the enrollment of the first patient in AVIDA, a registry for patients treated with Vidaza (azacitidine for injectable suspension). ... Pay-Per-View - Company Reports - Factiva, from Dow Jones European Commission Grants VIDAZA® Full Marketing Authorization for … - Dec 23, 2008 ...“The European Commission approval of VIDAZA is recognition of the significant survival benefit afforded by this therapy for critical haematologic ... Genetic Engineering News - Genetic Engineering News (press release) Clinical Data Reported on Vidaza in Hematologic Malignancies and … - Jun 2, 2007 CHICAGO, June 2 /PRNewswire-FirstCall/ -- Pharmion Corporation reported today the interim results of several Vidaza(R) (azacitidine for injection) studies ... Free with registration - PR Newswire - AccessMyLibrary.com … Nippon Shinyaku Announce Licensing Agreement for Vidaza(R) in Japan - Nov 21, 2006 ..."This licensing partnership validates the potential for Vidaza in Japan." Vidaza is marketed by Pharmion Corp. in the US, and by distributor partners in ... RedOrbit Press Release: Clinical Data on Vidaza(R) (Azacitidine for Injectable... - Dec 8, 2005 Clinical Data on Vidaza(R) (Azacitidine for Injectable Suspension) in Higher-Risk MDS, AML and Other Hematological Malignancies to be Presented at the ... Pay-Per-View - PR Newswire - HighBeam Research Study of VIDAZA(R) in Higher-Risk Myelodysplastic Syndrome Patients … - Jun 3, 2008 Celgene Corporation (Nasdaq:CELG) today announced updated results from a Phase III international clinical trial of VIDAZA in patients with myelodysplastic ... RedOrbit Pharmion CEO will stay in Colo., start another biotech - Nov 20, 2007 Celgene will acquire the rights to Vidaza, a drug Pharmion sells domestically ... Vidaza will complement Celgene's existing treatments for early-stage MDS. ... Bizjournals.com Press Release: Clinical Data on Vidaza(R) (Azacitidine for Injectable... - Jun 4, 2006 Clinical Data on Vidaza(R) (Azacitidine for Injectable Suspension) in Various Hematologic and Solid Tumor Cancers Presented at the American Society of ... Pay-Per-View - PR Newswire - HighBeam Research Pharmion Confirms Vidaza(R) European Regulatory Status. - Nov 17, 2005 BOULDER, Colo., Nov. 17 /PRNewswire-FirstCall/ -- Pharmion Corporation , as previously announced, confirmed that the European regulatory authorities will ... Free with registration - PR Newswire - AccessMyLibrary.com … gegevens over REVLIMID en VIDAZA in bloedkankersoorten gep.. - Jun 17, 2008 This improved survival with VIDAZA was supported by significant improvements ... In aggregate, the survival benefit for VIDAZA across all countries was 24.4 ... Netherlands Corporate News - Netherlands Corporate News (persbericht) SAC Capital raises stake in Pharmion - Dec 27, 2007 The company in August said a late-stage trial of its blood disorder drug Vidaza significantly extended the life of patients. (Reporting by Emily Chasan; ... Reuters Press Release: New Data Validate Vidaza(R) Response Rates in MDS … - Dec 11, 2006 New Data Validate Vidaza(R) Response Rates in MDS and Report Results in AML. from PR Newswire. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire - HighBeam Research Pharmion stops loss Denver Business Journal - Jul 25, 2005 Pharmion (NASDAQ: PHRM) launched US sales of Vidaza last year, and revenues for the drug hit $31.5 million in the second quarter. ... Denver Business Journal SAC Capital slashes Pharmion stake - Mar 6, 2008 MGI Pharma Inc. (nasdaq: MOGN - news - people ) is conducting additional trials for Dacogen, which is similar to Pharmion's blood-cancer treatment Vidaza. ... Forbes … Announces Enrollment of First Patient Into Vidaza(R) Patient... - Nov 1, 2006 Vidaza was approved in May 2004 for the treatment of all five French-American-British ... Article: Pharmion Corporation Announces Submission of Vidaza NDA . ... Pay-Per-View - PR Newswire - HighBeam Research Acquisition Charges Hit Celgene - May 8, 2008 European regulators recently granted marketing approval for Pharmion's Vidaza, a treatment for myelodysplastic syndrome (MDS), a pre-cancerous blood cell ... TheStreet.com - TheStreet.com (subscription) Pharmion Reports Third Quarter 2005 EPS of $0.27, Nine Month EPS of … - Oct 25, 2005 Sales of Vidaza totaled $92.0 million in the first nine months of 2005, compared to $20.4 ... This includes expected Vidaza sales of $123 to $127 million, ... $4.95 - PR Newswire - ECNext … Nippon Shinyaku Announce Licensing Agreement for Vidaza(R) in Japan - Nov 20, 2006 ..."This licensing partnership validates the potential for Vidaza in Japan ." Vidaza is marketed by Pharmion Corp. in the US, and by distributor partners in ... Genetic Engineering News - Genetic Engineering News (press release) New Administration Route Approved for Vidaza - Jan 31, 2007 The FDA has approved Pharmion Corporation's SNDA for Vidaza (azacitidine) injection for the addition of intravenous use as a route of administration. ... Facts and Comparisons FDA Approves Vidaza Label Expansion - Aug 22, 2008 The Aplastic Anemia & MDS International Foundation (AA&MDSIF) is pleased to inform patients that the US Food & Drug Administration (FDA) has expanded the ... Medical News Today - Medical News Today (press release) VIDAZA STRONG BUT LANDSCAPE CHANGING FOR MDS THERAPIES … - Mar 3, 2005 If a recent survey of 100 hematologists and oncologists is any indicator, then Vidaza (azacitidine), Pharmion Corp.'s pyrimidine nucleoside analogue ... Pay-Per-View - BIOWORLD Today - Factiva, from Dow Jones … Corporation Announces FDA Acceptance of Vidaza NDA Supplement for ... - Jun 13, 2006 Pharmion Corporation Announces FDA Acceptance of Vidaza NDA Supplement for IV Administration for Filing and Grants Six Month Review Goal. from PR Newswire. Pay-Per-View - PR Newswire - HighBeam Research => Clinical Data Reported on Vidaza in Hematologic Malignancies and … - Mar 6, 2007 CHICAGO, June 2 /PRNewswire-FirstCall/ -- Pharmion Corporation reported today the interim results of several Vidaza(R) (azacitidine for injection) studies ... FinanzNachrichten.de … MDS Stichting ondersteunt Europese goedkeuringsaanvraag voor Vidaza - Oct 27, 2008 The AZA-001 trial also showed that, VIDAZA delays the progression of MDS to acute myeloid leukemia (AML). Roughly 30 percent of patient diagnosed with MDS ... Netherlands Corporate News - Netherlands Corporate News (persbericht) Pharmion wants European OK - Jan 14, 2008 Biotechnology company Pharmion Corp. seeks to have its drug Vidaza approved in ... Vidaza is already approved in Europe to treat acute myeloid leukemia. ... Bizjournals.com … Corporation Announces Submission of Vidaza NDA Supplement for IV … - Mar 30, 2006 Pharmion Corporation Announces Submission of Vidaza NDA Supplement for IV Administration. from PR Newswire. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire - HighBeam Research Pharmion figures turn around in Q1 - Apr 26, 2005 Pharmion (Nasdaq: PHRM) launched sales of Vidaza July 1 last year, and revenues for ... "We are currently implementing our second wave of Vidaza marketing ... Denver Business Journal MDS Patients on Five-Day Vidaza(R) Dosing Schedules Achieve … - Dec 12, 2007 Pharmion Corporation (NASDAQ:PHRM) today announced interim data from a Phase 2 clinical trial evaluating three alternative five-day dosing schedules for ... Cancer Focus EU Grants VIDAZA® Full Marketing Authorization For The Treatment Of … - Dec 30, 2008 ..."The European Commission approval of VIDAZA is recognition of the significant survival benefit afforded by this therapy for critical haematologic ... Medical News Today - Medical News Today (press release) Netherlands Corporate News - VIDAZA-studie naar patiÄ—nten met … - Jun 6, 2008 ...( BW)(NJ-CELGENE)(CELG) Study of VIDAZA(R) in Higher-Risk Myelodysplastic Syndrome Patients Demonstrates Improved Overall Survival Business Editors/Health ... Netherlands Corporate News - Netherlands Corporate News (persbericht) … : New Data Demonstrate Clinical Activity of Vidaza(R) in Combination... - Dec 11, 2006 New Data Demonstrate Clinical Activity of Vidaza(R) in Combination With HDAC Inhibitors in the Treatment of Higher-Risk MDS and AML. from PR Newswire. Pay-Per-View - PR Newswire - HighBeam Research … Release: EMEA Accepts for Review Vidaza(R) Marketing Authorization... - Feb 7, 2008 EMEA Accepts for Review Vidaza(R) Marketing Authorization Application for Higher-Risk Myelodysplastic Syndromes. from PR Newswire. Pay-Per-View - PR Newswire - HighBeam Research Press Release: MDS Patients on Five-Day Vidaza(R) Dosing Schedules … - Dec 11, 2007 MDS Patients on Five-Day Vidaza(R) Dosing Schedules Achieve Transfusion Independence Consistent with Seven-day Schedule. from PR Newswire. Pay-Per-View - PR Newswire - HighBeam Research … Corporation Announces FDA Approval of Vidaza NDA Supplement for IV... - Jan 29, 2007 Pharmion Corporation Announces FDA Approval of Vidaza NDA Supplement for IV Administration. from PR Newswire. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire - HighBeam Research Press Release: Vidaza Significantly Extends Overall Survival by 74%... - Aug 2, 2007 Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS). from PR Newswire. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire - HighBeam Research … of a Phase I Study of REVLIMID® and VIDAZA® in Higher-Risk MDS … - Sep 12, 2008 Celgene International Sà rl (NASDAQ: CELG) reported that results of a Phase I study presented today combining REVLIMID and VIDAZA in patients with ... FINANZEN.NET NEWS - FINANZEN.NET NEWS Press Release: Clinical Data on Vidaza(R) (Azacitidine for Injectable... - Jun 4, 2006 Clinical Data on Vidaza(R) (Azacitidine for Injectable Suspension) in Various Hematologic and Solid Tumor Cancers Presented at the American Society of ... Pay-Per-View - PR Newswire Europe - HighBeam Research Pharmion narrow loss prior to Celgene acquisition - Feb 19, 2008 Worldwide sales of the company's blood-cancer treatment, Vidaza, ... Vidaza is used to treat myelodysplastic syndrome, or MDS, a bone marrow disease. nj.com … Marketing Authorization Application (MAA) for Vidaza(R) in... - Jan 14, 2008 Vidaza therapy confers highly significant 9.4 month median overall survival ... Two year overall survival rate of 50.8% for Vidaza compared to 26.2% for ... Pay-Per-View - PR Newswire - HighBeam Research … bids $2.9B for Pharmion; deal includes predicted blockbuster Vidaza... - Nov 26, 2007 According to the firms, Vidaza will be a strong strategic fit with Celgene's existing ... Vidaza, which is approved in the USA for MDS, has demonstrated ... $9.94 - Pharma Marketletter - Alacra Store … II Combination Clinical Trial With MGCD0103 and Vidaza(R) in... - Jan 9, 2008 Patients will receive 75 mg/m2 of Vidaza either intravenously or ... In this trial, we are combining Vidaza, our DNA methyltransferase inhibitor, ... Web Services Journal - Web Services Journal Vidaza still MDS winner, but market seems roomy. - Aug 29, 2005 The clock is ticking on key decisions related to a pair of drugs for myelodysplastic syndrome (MDS)--MGI Pharma Inc.'s Dacogen and Celgene Corp. ... Pay-Per-View - Bioworld Financial Watch - Factiva, from Dow Jones Press Release: New Data Validate Vidaza(R) Response Rates in MDS … - Dec 11, 2006 New Data Validate Vidaza(R) Response Rates in MDS and Report Results in AML. from PR Newswire Europe. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire Europe - HighBeam Research … : New Data Demonstrate Clinical Activity of Vidaza(R) in Combination... - Dec 11, 2006 New Data Demonstrate Clinical Activity of Vidaza(R) in Combination With HDAC Inhibitors in the Treatment of Higher-Risk MDS and AML. Pay-Per-View - PR Newswire Europe - HighBeam Research Celgene Savors the Schadenfreude - Jul 4, 2008 3 drug, Vidaza, got a competitive boost from a rival's setback. Vidaza has been locked in a bitter showdown with Eisai and SuperGen 's (Nasdaq: SUPG) ... Money Times - The Money Times Pharmion Corporation 2006 Investor/Analyst Meeting - Part 3. - Nov 2, 2006 So as Patrick alluded to, we've begun many other Vidaza combination studies. ... And here's an interesting intra-portfolio combination combining Vidaza with ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com FDA approves Pharmion's Vidaza for IV use. - Feb 5, 2007 FDA approves Pharmion's Vidaza for IV use. Colorado, USA-based biopharmaceutical firm Pharmion says that the Food and Drug Administration has approved an ... $9.94 - Pharma Marketletter - Alacra Store … Will Initiate First Head-to-Head Study Comparing Dacogen and Vidaza... - Apr 12, 2008 Patients will be randomized on a 1:1 ratio to either Dacogen or Vidaza. Each treatment arm will be stratified by IPSS risk group and type of MDS (primary ... The FINANCIAL Mylotarg® and Vidaza® Effective for Elderly with AML or MDS - Dec 9, 2006 Researchers from Loyola University have reported that the combination of Mylotarg® (gemtuzumab ozogamicin) and Vidaza® (azacitidine) has a high rate of ... Cancer Consultants … Data Demonstrating Significant Survival Advantage of Vidaza(R) in... - Dec 9, 2007 Two Year Overall Survival Rate of 50.8% for Vidaza Compared to 26.2% for Conventional ... The median overall survival advantage for Vidaza-treated patients ... Pay-Per-View - PR Newswire - HighBeam Research Pharmion Third Quarter Financial Results - Final.(Financial report) - Oct 31, 2007 Turning now to our development pipeline, and first to Vidaza. ... In the primary endpoint analysis, Vidaza treatment was associated with a median overall ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com (ΞÎνη δημοσίευση)-ΑÎ?ΑΚΟΙÎ?ΩΣΗ ΤΥΠΟΥ-BW-Celgene International Sarl - Dec 9, 2008 ASH Presentation of a Phase I Study of REVLIMID? and VIDAZA? in Higher-Risk MDS ... In May 2004, VIDAZA became the first drug approved by the FDA for the ... Αθηναικο Î Ï?ακτοÏ?είο Ειδήσεων - Αθηναικο Î Ï?ακτοÏ?είο Ειδήσεων Phamion Releases Data From Vidaza Phase III Study - Aug 6, 2007 Pharmion announced topline results from a Phase III trial of Vidaza versus conventional care regimens (CCR) in patients with higher-risk myelodysplastic ... FDA news - FDA news (subscription) Q3 2006 Pharmion Corporation Earnings Presentation - Part 2. - Oct 2, 2006 And secondly on Vidaza IV, which we're still waiting for and it sounds like ... As you may all know, Vidaza was originally -- in the original trials with ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com … (CELG) Reports Data from Phase III Trial of VIDAZA(R) Shows... - Dec 8, 2008 Celgene International Sarl (NASDAQ: CELG) reports that an analysis presented today of a phase III international clinical trial (AZA-001) of higher-risk ... StreetInsider.com - StreetInsider.com (subscription) … (PHRM) Receives FDA Approval of Vidaza NDA Supplement for IV … - Jan 29, 2007 Pharmion Corporation (Nasdaq: PHRM) has received approval from the US Food and Drug Administration (FDA) for its new drug application (NDA) supplement to ... StreetInsider.com - StreetInsider.com (subscription) The Vidaza survival benefit news is a positive for MGI Pharma's Daco ... - Nov 19, 2007 There is no reason to believe Dacogen is inferior to Vidaza. In some studies, Dacogen seems to produce a deeper quality of response, and may also prove more ... Gerson Lehrman Group Vidaza launch boost Pharmion's 4th qtr.(pharmaceutical industry)(Brief... - Feb 21, 2005 Pharmion Corp of the USA says that fourth-quarter 2004 net sales totaled $51.5 million, compared to $11.8 million in the like period of 2003. ... $4.95 - Pharma Marketletter - ECNext European panel gives thumbs up to Celgene's cancer drug Vidaza - Oct 24, 2008 ...by Jeff May/The Star-Ledger. A European drug advisory panel has recommended approval of Celgene's Vidaza as a treatment for patients with various blood ... nj.com Vidaza, Only Agent To Extend Survival In Patients With Higher-Risk … - Aug 27, 2008 The Myelodysplastic Syndromes (MDS) Foundation supports the decision by the US Food & Drug Administration (FDA) to extend the label for VIDAZA (azacitidine) ... Medical News Today - Medical News Today (press release) Celgene Gets OK to Expand Vidaza Label - Aug 29, 2008 The FDA has approved expanding the label for Celgene's Vidaza to include new overall survival data from a Phase III study of patients with higher risk ... FDA news - FDA news (subscription) MethylGene Provides Corporate Update at its Investor Event - Oct 2, 2007 This trial will test the combination of MGCD0103 and Vidaza ® against MGCD0103 as a single agent and Vidaza ® as a single agent. The protocol is an adaptive ... marketwire.com Vidaza.(NEW LABELING)(Brief article) - Mar 5, 2007 Pharmion Corp., Boulder, Colo., (720) 564-9100, has received FDA approval to change the instructions in its prescribing information for Vidaza (azacitidine ... Free with registration - Drug Topics - AccessMyLibrary.com Press Release: Pharmion to Present Clinical Data on Key Hematology … - Dec 6, 2007 Data Presentations Highlight Overall Survival Results of Vidaza(R) in ... Additionally, data from a study of Vidaza in combination with MGCD0103 in MDS and ... Pay-Per-View - PR Newswire - HighBeam Research Q4 2005 Pharmion Corporation Earnings Conference Call - Final. - Feb 22, 2006 Additionally we plan a submission from the Vidaza survival study to expand ... Moving now to Vidaza. Our Phase III-IV survival study in 354 high risk MDS ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com … Release: Clinical Data Reported on Vidaza in Hematologic Malignanci... - Jun 2, 2007 Clinical Data Reported on Vidaza in Hematologic Malignancies and Advanced Solid Tumors. from PR Newswire. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire - HighBeam Research Celgene Reports Positive Results From Sub-Analysis of Myelodysplastic... - Jun 16, 2008 This improved survival with Vidaza was supported by significant improvements in hematologic response, and improvement in transfusion independence. RedOrbit Pharmion and MethylGene Announce Collaboration to Develop Sirtuin … - Aug 20, 2007 ..."With the recent survival data demonstrated by Vidaza in higher-risk MDS, epigenetic therapies are rapidly emerging as an important component of cancer ... MedIndia Vidaza.(FDA actions in brief)(treatment for myelodysplastic syndromes... - Mar 1, 2007 Azacitidine (Vidaza, Pharmion) was approved for intravenous injection for the treatment of patients with myelodysplastic syndromes, including the subtypes ... Free with registration - Formulary - AccessMyLibrary.com Pharmion grants Japanese Vidaza rights to Nippon Shinyaku.(Brief... - Nov 27, 2006 The USA's Pharmion Corp has licensed Vidaza (azacitidine for injectable suspension), its drug for myeoldysplastic syndromes, to Nippon Shinyaku. ... Free with registration - Pharma Marketletter - AccessMyLibrary.com … Start Phase 2 Combination Clinical Trial With MGCD0103 and Vidaza(R... - Jan 9, 2008 Patients will receive 75 mg/m2 of Vidaza either intravenously or ... CELG) today announced that data showed VIDAZA (azacitidine) provides a significant . ... Pay-Per-View - PR Newswire - HighBeam Research |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |